Abstract
ObjectivesTo report the efficacy, safety and patient-reported outcome measures (PROs) of tofacitinib modified-release 11 mg once daily plus methotrexate in patients with rheumatoid arthritis (RA) from the open-label phase of...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have